Literature DB >> 9701014

Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.

H Tsuda1, S Hirohashi.   

Abstract

To determine the developmental stages at which the highly malignant phenotype of breast carcinoma is acquired, the histological grade and c-erbB-2 oncoprotein expression status were examined for both the ductal carcinoma in situ (DCIS) and invasive components of 437 separate invasive breast carcinomas. In 218 invasive carcinomas with high-grade atypia (grade 3), the DCIS components were grade 2-3 in 158 cases (73%). Twenty-seven (12%) showed an obvious stepwise increase from grade 1 DCIS to grade 3 invasive carcinoma, and 25 of these tumors had DCIS components covering < 25% of their area. Ductal carcinoma in situ components were undetectable in 33 (15%) of invasive carcinomas. The incidence of c-erbB-2 overexpression was higher in grade 3 carcinomas with grade 2-3 DCIS components (55%, 80 of 146) than in those with grade 1 DCIS components (5%, one of 25). The incidence was also higher in grade 3 carcinomas with DCIS components covering > or =25% of the tumor area (71%, 39 of 55) than in those with DCIS over < 25% of the total area (36%, 42 of 116) or without DCIS components (6%, two of 33). There appeared to be three prototypic pathways to high-grade breast carcinoma: (i) invasion by a high-grade DCIS regardless of the extent of DCIS spread; (ii) invasion by a low-grade DCIS during the microscopic stages, accompanied by an obvious enhancement of the grade; and (iii) development of an invasive carcinoma ab initio. c-erbB-2 overexpression appeared to be frequently involved in the early development of the first group but showed little relation to the invasive process in any of these three pathways. The histological grade and c-erbB-2 overexpression appeared to be largely established during the early microscopic stages of a DCIS or invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701014     DOI: 10.1111/j.1440-1827.1998.tb03943.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

2.  The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n-3 PUFAs.

Authors:  Lisa D Yee; Deepak Agarwal; Thomas J Rosol; Amy Lehman; Min Tian; Jennifer Hatton; Jessica Heestand; Martha A Belury; Steven K Clinton
Journal:  Mol Nutr Food Res       Date:  2012-12-05       Impact factor: 5.914

3.  Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

Authors:  Min Wu; Lina Jung; Adrian B Cooper; Christina Fleet; Lihao Chen; Lyne Breault; Kimberly Clark; Zuhua Cai; Sylvie Vincent; Steve Bottega; Qiong Shen; Andrea Richardson; Marcus Bosenburg; Stephen P Naber; Ronald A DePinho; Charlotte Kuperwasser; Murray O Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-15       Impact factor: 11.205

4.  Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.

Authors:  Seung-Hyun Jung; Ahwon Lee; Seon-Hee Yim; Hae-Jin Hu; Chungyoul Choe; Yeun-Jun Chung
Journal:  BMC Cancer       Date:  2012-08-31       Impact factor: 4.430

5.  Protein biomarkers for the early detection of breast cancer.

Authors:  David E Misek; Evelyn H Kim
Journal:  Int J Proteomics       Date:  2011-08-11

Review 6.  Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.

Authors:  Flora Zagouri; Theodoros N Sergentanis; George C Zografos
Journal:  World J Surg Oncol       Date:  2007-05-31       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.